Terms: = Skin cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
760 results:
1. Inflammatory breast cancer: An overview about the histo-pathological aspect and diagnosis.
Sahraoui G; Rahoui N; Driss M; Mrad K
Int Rev Cell Mol Biol; 2024; 384():47-61. PubMed ID: 38637099
[TBL] [Abstract] [Full Text] [Related]
2. Naringenin Induces Cellular Apoptosis in Melanoma Cells
Fernando PDSM; Zhen AX; Piao MJ; Herath HMUL; Kang KA; Yoon SP; Boo HJ; Hyun CL; Hyun JW
Anticancer Res; 2024 Mar; 44(3):1079-1086. PubMed ID: 38423648
[TBL] [Abstract] [Full Text] [Related]
3. Lamivudine, Doravirine, and Cabotegravir Downregulate the Expression of Human Endogenous Retroviruses (HERVs), Inhibit Cell Growth, and Reduce Invasive Capability in Melanoma Cell Lines.
Zanrè V; Bellinato F; Cardile A; Passarini C; Monticelli J; Di Bella S; Menegazzi M
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338893
[TBL] [Abstract] [Full Text] [Related]
4. Inhibition of Autophagy Aggravates
Tsai CH; Huang HC; Lin KJ; Liu JM; Chen GL; Yeh YH; Lu TL; Lin HW; Lu MT; Chu PC
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279345
[TBL] [Abstract] [Full Text] [Related]
5. Differential Regulation of Circadian Clock Genes by UV-B Radiation and 1,25-Dihydroxyvitamin D: A Pilot Study during Different Stages of skin Photocarcinogenesis.
Lamnis L; Christofi C; Stark A; Palm H; Roemer K; Vogt T; Reichrath J
Nutrients; 2024 Jan; 16(2):. PubMed ID: 38257148
[TBL] [Abstract] [Full Text] [Related]
6. FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models.
Galpin KJC; Rodriguez GM; Maranda V; Cook DP; Macdonald E; Murshed H; Zhao S; McCloskey CW; Chruscinski A; Levy GA; Ardolino M; Vanderhyden BC
Sci Rep; 2024 Jan; 14(1):787. PubMed ID: 38191799
[TBL] [Abstract] [Full Text] [Related]
7. Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
Ahn IE; Brander DM; Ren Y; Zhou Y; Tyekucheva S; Walker HA; Black R; Montegaard J; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng SY; Crombie J; Fisher DC; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Brown JR; Davids MS
Blood Adv; 2024 Feb; 8(4):832-841. PubMed ID: 38163317
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study.
Deng L; Wang HY; Hu CF; Liu XY; Jiang K; Yong JJ; Wu XY; Guo KH; Wang F
Pigment Cell Melanoma Res; 2024 May; 37(3):363-371. PubMed ID: 38158377
[TBL] [Abstract] [Full Text] [Related]
9. A cytosolic mutp53(E285K) variant confers chemoresistance of malignant melanoma.
Dunsche L; Ivanisenko N; Riemann S; Schindler S; Beissert S; Angeli C; Kreis S; Tavassoli M; Lavrik I; Kulms D
Cell Death Dis; 2023 Dec; 14(12):831. PubMed ID: 38097548
[TBL] [Abstract] [Full Text] [Related]
10. Establishment and Characterization of a tp53-Mutated Eyelid Sebaceous Carcinoma Cell Line.
Gu X; Huang Z; Chen J; Luo Y; Ge S; Jia R; Song X; Chai P; Xu S; Fan X
Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):16. PubMed ID: 38095907
[TBL] [Abstract] [Full Text] [Related]
11. Comparing p53 expression and genome-wide transcriptome profiling to Comet assay in lymphocytes from melanoma patients and healthy controls.
Najafzadeh M; Naeem P; Ghaderi N; Jafarinejad S; Karimi Z; Ghaderi M; Akhbari P; Ghaderi R; Farsi P; Wright A; Anderson D
Sci Rep; 2023 Nov; 13(1):18858. PubMed ID: 37914759
[TBL] [Abstract] [Full Text] [Related]
12. Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin.
Olafsson S; Rodriguez E; Lawson ARJ; Abascal F; Huber AR; Suembuel M; Jones PH; Gerdes S; Martincorena I; Weidinger S; Campbell PJ; Anderson CA
Nat Genet; 2023 Nov; 55(11):1892-1900. PubMed ID: 37884686
[TBL] [Abstract] [Full Text] [Related]
13. Tumor-infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer.
Jacover A; Zarbiv Y; Tal KH; Klein S; Breuer S; Durst R; Avni B; Grisariu S; Stepensky P; Lotem M; Maimon O; Yablonski-Peretz T
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1894. PubMed ID: 37750497
[TBL] [Abstract] [Full Text] [Related]
14. Current and preclinical treatment options for Merkel cell carcinoma.
Celikdemir B; Houben R; Kervarrec T; Samimi M; Schrama D
Expert Opin Biol Ther; 2023; 23(10):1015-1034. PubMed ID: 37691397
[TBL] [Abstract] [Full Text] [Related]
15. A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG.
Miranda J; Vázquez-Blomquist D; Bringas R; Fernandez-de-Cossio J; Palenzuela D; Novoa LI; Bello-Rivero I
BMC Cancer; 2023 Aug; 23(1):806. PubMed ID: 37644431
[TBL] [Abstract] [Full Text] [Related]
16. Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
Znaider VK; Mikkelsen LH; Jensen CFS; Sønksen J; Heegaard S
Scand J Urol; 2023 Aug; 58():52-59. PubMed ID: 37635444
[TBL] [Abstract] [Full Text] [Related]
17. Potential Therapeutic Targets of Quercetin in the Cutaneous Melanoma Model and Its Cellular Regulation Pathways: A Systematic Review.
Salgado MTSF; Fernandes E Silva E; Nascimento MAD; Lopes AC; Paiva LS; Votto APS
Nutr Cancer; 2023; 75(9):1687-1709. PubMed ID: 37553896
[TBL] [Abstract] [Full Text] [Related]
18. The anti-cancer effect and mechanism of animal scale-derived extract on malignant melanoma cells.
Song L; Li C; Yu J; Yang Y; Tian X; Choo SW
Sci Rep; 2023 Aug; 13(1):12548. PubMed ID: 37532809
[TBL] [Abstract] [Full Text] [Related]
19. Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies.
Najem A; Krayem M; Sabbah S; Pesetti M; Journe F; Awada A; Désaubry L; Ghanem GE
Cells; 2023 Jul; 12(14):. PubMed ID: 37508519
[TBL] [Abstract] [Full Text] [Related]
20. Impact of Aluminium phthalocyanine nanoconjugate on melanoma stem cells.
Mkhobongo B; Chandran R; Abrahamse H
Artif Cells Nanomed Biotechnol; 2023 Dec; 51(1):334-345. PubMed ID: 37455406
[TBL] [Abstract] [Full Text] [Related]
[Next]
